IN2014MN02156A - - Google Patents

Info

Publication number
IN2014MN02156A
IN2014MN02156A IN2156MUN2014A IN2014MN02156A IN 2014MN02156 A IN2014MN02156 A IN 2014MN02156A IN 2156MUN2014 A IN2156MUN2014 A IN 2156MUN2014A IN 2014MN02156 A IN2014MN02156 A IN 2014MN02156A
Authority
IN
India
Prior art keywords
acid
microparticles
alfentanil
presented
pain
Prior art date
Application number
Other languages
English (en)
Inventor
Anders Pettersson
Emil Schwan
Barbro Johansson
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48577134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN02156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1207701.2A external-priority patent/GB201207701D0/en
Priority claimed from GBGB1221130.6A external-priority patent/GB201221130D0/en
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of IN2014MN02156A publication Critical patent/IN2014MN02156A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2156MUN2014 2012-05-02 2013-05-01 IN2014MN02156A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1207701.2A GB201207701D0 (en) 2012-05-02 2012-05-02 New pharmaceutical composition
GBGB1221130.6A GB201221130D0 (en) 2012-11-23 2012-11-23 New pharmaceutical composition
PCT/GB2013/051131 WO2013164620A1 (fr) 2012-05-02 2013-05-01 Nouvelle composition d'alfentanil pour le traitement d'une douleur aiguë

Publications (1)

Publication Number Publication Date
IN2014MN02156A true IN2014MN02156A (fr) 2015-08-28

Family

ID=48577134

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2156MUN2014 IN2014MN02156A (fr) 2012-05-02 2013-05-01

Country Status (34)

Country Link
US (4) US8815911B2 (fr)
EP (2) EP2849730B1 (fr)
JP (1) JP6275696B2 (fr)
KR (1) KR20150005695A (fr)
CN (1) CN104427978B (fr)
AU (1) AU2013255640B2 (fr)
BR (1) BR112014027213A8 (fr)
CA (1) CA2871805A1 (fr)
CL (1) CL2014002979A1 (fr)
CO (1) CO7170181A2 (fr)
CY (2) CY1118570T1 (fr)
DK (2) DK3150199T3 (fr)
EA (1) EA028110B1 (fr)
ES (2) ES2694644T3 (fr)
HK (1) HK1203399A1 (fr)
HR (2) HRP20161634T1 (fr)
HU (1) HUE031792T2 (fr)
IL (1) IL235272B (fr)
IN (1) IN2014MN02156A (fr)
LT (2) LT3150199T (fr)
ME (1) ME02644B (fr)
MX (1) MX360665B (fr)
NZ (1) NZ701428A (fr)
PE (1) PE20142444A1 (fr)
PH (1) PH12014502407B1 (fr)
PL (2) PL2849730T3 (fr)
PT (2) PT3150199T (fr)
RS (2) RS55489B1 (fr)
SG (1) SG11201407081PA (fr)
SI (2) SI3150199T1 (fr)
SM (1) SMT201700086B (fr)
TR (1) TR201815935T4 (fr)
WO (1) WO2013164620A1 (fr)
ZA (1) ZA201407559B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2915525T3 (pl) 2011-09-19 2022-01-17 Orexo Ab Tabletki podjęzykowe niepodatne na nadużywanie zawierające buprenorfinę i nalokson
PL2849730T3 (pl) * 2012-05-02 2017-05-31 Orexo Ab Nowa kompozycja zawierająca alfentanyl do leczenia ostrego bólu
US10766925B2 (en) * 2016-04-11 2020-09-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Opioid receptor modulators
JP7023054B2 (ja) * 2017-04-05 2022-02-21 東和薬品株式会社 レベチラセタム含有医薬組成物及びその製造方法
CN115047109B (zh) * 2022-06-17 2024-05-31 三明海关综合技术服务中心 一种检测食品中芬太尼类新精神活性物质的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
DE19749724A1 (de) 1997-11-11 1999-06-10 Gruenenthal Gmbh Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
GB9904911D0 (en) 1999-03-03 1999-04-28 Scherer Ltd R P Pharmaceutical compositions
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20020160043A1 (en) 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
EP1587514B3 (fr) 2003-01-31 2011-06-22 Orexo AB Composition pharmaceutique a effet rapide
ES2414084T3 (es) 2003-02-24 2013-07-18 Pharmaceutical Productions Inc. Sistema de administración de fármacos por vía transmucosa
US20050042281A1 (en) 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
WO2005065319A2 (fr) 2003-12-31 2005-07-21 Cima Labs Inc. Forme galenique de fentanyl generalement lineaire effervescente et orale et ses procedes d'administration
US7858121B2 (en) * 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
US20070036853A1 (en) 2003-12-31 2007-02-15 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
AU2004311879B2 (en) 2003-12-31 2010-08-05 Cima Labs Inc. Effervescent oral opiate dosage form
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
EP1863456A1 (fr) 2005-03-28 2007-12-12 Orexo AB Nouvelles compositions pharmaceutiques utiles dans le traitement de la douleur
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
US20070104763A1 (en) * 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8535714B2 (en) * 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US20070286900A1 (en) 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
US20100233257A1 (en) 2006-06-09 2010-09-16 Ethypharm Low dose sublingual tablets of opioid analgesics and preparation process
DK2054031T3 (en) * 2006-07-21 2016-05-17 Biodelivery Sciences Int Inc Transmucosal delivery devices with improved uptake
JP5484062B2 (ja) * 2006-12-04 2014-05-07 オレクソ・アクチエボラゲット オピオイドを含む新規の非−乱用性医薬組成物
EP1964564A1 (fr) 2007-04-19 2008-09-03 LAB International SRL Gestion efficace de la douleur
KR101606944B1 (ko) 2007-08-07 2016-03-28 아셀알엑스 파마슈티컬스 인코퍼레이티드 경구 경점막 투여형을 사용한 시술시 진정과 무통을 위한 조성물 및 방법
US20090263476A1 (en) * 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
US8343978B2 (en) 2008-08-04 2013-01-01 Adds Pharmaceuticals Llc Fast onset orodispersable tablets
US20100056574A1 (en) 2008-09-04 2010-03-04 Mallinckrodt Inc. Crystalline Forms of Sufentanil
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
EP2429503A1 (fr) 2009-05-13 2012-03-21 Protein Delivery Solutions, LLC Systeme pharmaceutique pour l'administration transmembranaire
WO2010141505A1 (fr) 2009-06-01 2010-12-09 Protect Pharmaceutical Corporation Systèmes d'administration résistants aux abus
JP2009280611A (ja) * 2009-08-26 2009-12-03 Kyukyu Yakuhin Kogyo Kk 口腔内粘膜フィルム剤
US20110091544A1 (en) 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
WO2011057199A1 (fr) 2009-11-06 2011-05-12 Adenios, Inc. Compositions destinées à traiter des troubles du snc
US20110150989A1 (en) 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
PL2849730T3 (pl) * 2012-05-02 2017-05-31 Orexo Ab Nowa kompozycja zawierająca alfentanyl do leczenia ostrego bólu

Also Published As

Publication number Publication date
ME02644B (fr) 2017-06-20
CN104427978A (zh) 2015-03-18
HK1203399A1 (en) 2015-10-30
SMT201700086B (it) 2017-03-08
HUE031792T2 (en) 2017-07-28
HRP20181761T1 (hr) 2018-12-28
US20170071927A1 (en) 2017-03-16
US20150133501A1 (en) 2015-05-14
ES2694644T3 (es) 2018-12-26
SI3150199T1 (sl) 2018-12-31
CN104427978B (zh) 2017-03-01
PH12014502407A1 (en) 2015-01-12
US8815911B2 (en) 2014-08-26
EP3150199A1 (fr) 2017-04-05
US9782396B2 (en) 2017-10-10
RS57951B1 (sr) 2019-01-31
JP6275696B2 (ja) 2018-02-14
SG11201407081PA (en) 2014-11-27
AU2013255640A1 (en) 2014-11-20
WO2013164620A1 (fr) 2013-11-07
BR112014027213A2 (pt) 2017-06-27
PE20142444A1 (es) 2015-01-09
CL2014002979A1 (es) 2014-12-05
PH12014502407B1 (en) 2015-01-12
CO7170181A2 (es) 2015-01-28
LT2849730T (lt) 2016-12-27
JP2015515974A (ja) 2015-06-04
DK3150199T3 (en) 2018-11-12
EP2849730A1 (fr) 2015-03-25
SI2849730T1 (sl) 2017-02-28
NZ701428A (en) 2016-10-28
IL235272B (en) 2018-10-31
US20180214437A1 (en) 2018-08-02
ZA201407559B (en) 2016-05-25
KR20150005695A (ko) 2015-01-14
EA201401200A1 (ru) 2015-02-27
RS55489B1 (sr) 2017-04-28
EP3150199B1 (fr) 2018-08-08
PT2849730T (pt) 2017-02-15
BR112014027213A8 (pt) 2018-01-16
TR201815935T4 (tr) 2018-11-21
US9345698B2 (en) 2016-05-24
CY1120820T1 (el) 2019-12-11
MX360665B (es) 2018-11-13
HRP20161634T1 (hr) 2017-01-13
CA2871805A1 (fr) 2013-11-07
MX2014013176A (es) 2015-01-19
DK2849730T3 (en) 2017-02-13
CY1118570T1 (el) 2017-07-12
PL3150199T3 (pl) 2019-03-29
AU2013255640B2 (en) 2017-06-15
US20140005223A1 (en) 2014-01-02
LT3150199T (lt) 2018-11-12
EA028110B1 (ru) 2017-10-31
PL2849730T3 (pl) 2017-05-31
PT3150199T (pt) 2018-11-21
EP2849730B1 (fr) 2016-11-09
ES2614757T3 (es) 2017-06-01

Similar Documents

Publication Publication Date Title
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
PH12015502002A1 (en) Tripeptide epoxy ketone protease inhibitors
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
IN2014DN10386A (fr)
MX348823B (es) Formulaciones estables de linaclotida.
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
EA201400246A1 (ru) Новая, не допускающая злоупотребления фармацевтическая композиция для лечения опиоидной зависимости
IN2012DN06720A (fr)
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
IN2015DN01164A (fr)
MX362489B (es) Inhibidores dipeptídicos y tripeptídicos de epoxi cetona proteasa.
IN2015DN01165A (fr)
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
WO2012098562A3 (fr) Compositions liquides pour administration par voie orale de sels de lanthane
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
IN2015DN03921A (fr)
PH12014502407A1 (en) New alfentanil composition for the treatment of acute pain
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
EA201401309A1 (ru) Фармацевтическая композиция для ингаляции, содержащая аклидиний, и её применение
EA201190282A1 (ru) Фармацевтическая композиция, содержащая тамсулозин
NZ701274A (en) Oral b12 therapy
WO2012108794A3 (fr) Dérivés de l'acide 1,2,4-triazol-з-yl-thioglycolique destinés à s'utiliser en thérapie